Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer, will lead a panel discussion at the World Anti-Microbial Resistance Congress in Washington, USA on 9 September 2016.
The discussion is titled: ‘In-licensing: Addressing the deficiencies in the original development program to develop a unique non-combination anti-infective’
For further information on the conference please see:
About Motif Bio
Motif Bio plc is a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections which are often caused by MRSA. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an IV formulation of iclaprim, for the treatment of ABSSSI.